...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in therapy. >Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes.
【24h】

Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes.

机译：那格列奈对2型糖尿病患者LDL颗粒大小的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of the present study was to evaluate the efficacy of nateglinide in controlling blood glucose levels and regulating lipid metabolism in patients with type 2 diabetes by focusing attention particularly on low-density lipoprotein (LDL) particle size. The subjects were 23 patients with type 2 diabetes who were given nateglinide, 90 to 270 mg/d. Laboratory studies were conducted at treatment initiation and 3 mo later. Despite a decline that occurred in the level of fasting plasma glucose before and after administration of nateglinide, no significant difference was recognized. Hemoglobin A1c decreased significantly from 6.37+/- 0.75% to 5.91+/-0.64% (P<.001). A significant decline was also seen in the fasting level of immunoreactive insulin, from 9.82+/-5.69 microU/mL to 8.59+/-4.05 microU/mL (P<.05), and in the homeostasis model assessment for insulin resistance, from 3.06+/-1.83 to 2.55+/-1.26 (P<.05). Regarding lipids, triglycerides significantly decreased from 140.7+/-61.8 mg/dL to 117.3+/-34.7 mg/dL )P<.05). The significant reduction in migration index value, which was used as an index to LDL particle size, from 0.374+/-0.034 to 0.357+/-0.035 (P<.05), confirmed that LDL particle size had increased. The results of the present study show that nateglinide is effective in controlling blood glucose and improving insulin resistance, hypertriglyceridemia, and LDL particle size in patients with mild type 2 diabetes. These effects suggest that nateglinide may effectively control coronary artery disease in this population.
机译：本研究的目的是通过特别关注低密度脂蛋白（LDL）粒径来评估那格列奈在控制2型糖尿病患者血糖水平和调节脂质代谢中的功效。受试者为23名2型糖尿病患者，分别接受90至270 mg / d那格列奈治疗。在治疗开始时和3 mo之后进行实验室研究。尽管给予那格列奈前后空腹血糖水平下降，但未发现明显差异。血红蛋白A1c从6.37 +/- 0.75％显着下降至5.91 +/- 0.64％（P <.001）。免疫反应性胰岛素的禁食水平也显着下降，从9.82 +/- 5.69 microU / mL降至8.59 +/- 4.05 microU / mL（P <.05），以及胰岛素抵抗的稳态模型评估从3.06 +/- 1.83至2.55 +/- 1.26（P <.05）。关于脂质，甘油三酸酯从140.7 +/- 61.8mg / dL显着降低至117.3 +/- 34.7mg / dL（P ＜0.05）。用作LDL粒径指标的迁移指数值从0.374 +/- 0.034显着降低至0.357 +/- 0.035（P <.05），证实LDL粒径有所增加。本研究的结果表明那格列奈可有效控制轻度2型糖尿病患者的血糖并改善胰岛素抵抗，高甘油三酯血症和LDL粒径。这些效果表明那格列奈可以有效控制这一人群的冠状动脉疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号